Fatigue and functional impairment in early-stage XXXX survivors.

@entity1 @entity308 @entity1149 @entity1295 @entity358 @entity148 @entity1030
CONTEXT: Fatigue is the most common sequela among @entity1149 ( @entity1149 ) survivors one to six years post-treatment and is associated with functional limitations. OBJECTIVES: This study examined the prevalence, severity, and correlates of @entity1295 among early stage @entity1149 survivors. METHODS: Three-hundred fifty individuals diagnosed and surgically treated for Stage IA or IB @entity1149 completed a survey that included the Brief Fatigue Inventory (BFI) to assess the prevalence and severity of @entity1295 . The Karnofsky Self-Reported Performance Rating scale (SR-KPS) was used as a measure of functional status and was compared with the severity of @entity1295 through Chi-squared analyses. Demographic, psychological, and medical correlates of @entity1295 were examined using logistic regression. RESULTS: The prevalence of @entity1295 was 57%. Forty-one percent (n=142) of @entity1 had mild @entity1295 and 16.8% (n=59) had moderate or severe @entity1295 (BFI>= 4). Among the individuals reporting moderate or severe @entity1295 , 23.7% (n=14) had significant functional impairment (SR-KPS <=70%) compared with 2.8% (n=8) with mild or no @entity1295 (  (2)=58.1, P<0.001). In the multivariate analysis, @entity1149 survivors with @entity358 (odds ratio [OR]=2.28), @entity308 (OR=6.99), and @entity148 (OR=2.31) were more likely to report experiencing clinically significant @entity1295 , whereas those who met physical activity guidelines (OR=0.29) reported less @entity1295 . CONCLUSION: Fatigue is highly prevalent among @entity1149 survivors and associated with more functional impairment. A comprehensive approach to the treatment of @entity1295 includes the screening and management of anxious and @entity308 , and @entity358 such as @entity1030 .
